Phaseline

Companies › Abbisko Therapeutics

Abbisko Therapeutics: clinical trials, targets and expected readouts

10 active drug programs in 18 registered trials: 10 Phase 1, 7 Phase 2, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pimicotinib capsule
CSF1R inhibitor
CSF1RPhase 3Tenosynovial Giant Cell Tumor; Healthy SubjectsJun 2028
ABSK-011 Capsules
FGF19 inhibitor
FGF19Phase 2Hepatocellular Carcinoma (HCC); Healthy Participants; Advanced Liver Cancer; HCC - Hepatocellular CarcinomaJun 2027
ABSK043
KRAS inhibitor
KRASPhase 2Non-Small Cell Lung Cancer With EGFR Mutation; Non-Small Cell Lung Cancer; NeoplasmsJul 2027
ABSK061
FGFR inhibitor
–Phase 2HER2-Gastric/Gastroesophageal Junction CancerNov 2029
ABSK-021–Phase 1NeoplasmsDec 2026
ABSK121-NX–Phase 1Solid TumorJan 2027
ABSK112
EGFR Exon20 inhibitor
EGFRPhase 1Non-Small Cell Lung CancerMar 2027
ABSK131
MTAP inhibitor
MTAPPhase 1Solid Tumors (Phase 1)Dec 2028
ABSK141–Phase 1Solid Tumors, AdultDec 2028
ABSK211
KRAS inhibitor
KRASPhase 1Solid Tumor (Phase I)Dec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06884072Pimicotinib capsulePhase 1Healthy SubjectsOtherJul 2025
NCT07700953ABSK-011 CapsulesPhase 1Healthy ParticipantsOtherAug 2026
NCT06978933ABSK-011 CapsulesPhase 2HCC - Hepatocellular CarcinomaOncologyDec 2026
NCT04192344ABSK-021Phase 1NeoplasmsOncologyDec 2026
NCT05627063ABSK121-NXPhase 1Solid TumorOncologyJan 2027
NCT06225804ABSK112Phase 1Non-Small Cell Lung CancerOncologyMar 2027
NCT07327034ABSK-011 CapsulesPhase 2Hepatocellular Carcinoma (HCC)OncologyJun 2027
NCT04964375ABSK043Phase 1NeoplasmsOncologyJul 2027
NCT06668103ABSK043Phase 2Non-Small Cell Lung Cancer With EGFR MutationOncologyDec 2027
NCT04906434ABSK-011 CapsulesPhase 1Advanced Liver CancerOncologyDec 2027
NCT05804045Pimicotinib capsulePhase 3Tenosynovial Giant Cell TumorOncologyJun 2028
NCT07164170ABSK043Phase 2Non-Small Cell Lung CancerOncologyDec 2028
NCT07164170ABSK043Phase 2Non-Small Cell Lung CancerOncologyDec 2028
NCT07417189ABSK141Phase 1Solid Tumors, AdultOncologyDec 2028
NCT07288957ABSK131Phase 1Solid Tumors (Phase 1)OncologyDec 2028
NCT06632262ABSK061Phase 2HER2-Gastric/Gastroesophageal Junction CancerOncologyNov 2029
NCT06632262ABSK061Phase 2HER2-Gastric/Gastroesophageal Junction CancerOncologyNov 2029
NCT07718165ABSK211Phase 1Solid Tumor (Phase I)OncologyDec 2029

Targets

KRAS (2) FGF19 (1) CSF1R (1) MTAP (1) EGFR (1)

Companies with the same targets

Revolution Medicines AstraZeneca Bristol-Myers Squibb Allist Pharmaceuticals Shanghai Henlius Biotech TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Amgen Novartis Quanta Therapeutics Incyte

Companies built like this

Jiangsu Alphamab Biopharmaceuticals DualityBio Avistone Biotechnology Nanjing Sanhome Pharmaceutical Betta Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.